Anticancer agents: towards the future.
A major need in cancer chemotherapy is the availability of cancer cell-specific drugs. This paper discusses recent advances and perspectives in the field of selective drug recognition considering the key targets tyrosine kinases, DNA-topoisomerases and telomerase.
Palumbo
Manlio
M
Department of Pharmaceutical Sciences, Via Marzolo, 5, 35131 Padova, Italy. manlio.palumbo@unipd.it
D000970:Antineoplastic Agents / Q000494:pharmacology*; D004247:DNA / Q000737:chemistry; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D016376:Oligonucleotides, Antisense / Q000737:chemistry; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D019098:Telomerase / Q000378:metabolism; D059004:Topoisomerase I Inhibitors
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D059004:Topoisomerase I Inhibitors; D004247:DNA; D011505:Protein-Tyrosine Kinases; D019098:Telomerase